Kristian Rennie

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Molecular detection of minimal residual disease (MRD) has become established to assess remission status and guide therapy in patients with ProMyelocytic Leukemia-RARA+ acute promyelocytic leukemia (APL). However, there are few data on tracking disease response in patients with rarer retinoid resistant subtypes of APL, characterized by PLZF-RARA and(More)
  • 1